• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Atlantic International Corp. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets

    3/26/26 5:00:07 PM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $ATLN alert in real time by email
    false --12-31 0001605888 0001605888 2026-03-20 2026-03-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported) March 20, 2026

     

    ATLANTIC INTERNATIONAL CORP.

    (Exact name of registrant as specified in charter)

     

    Delaware   001-40760   46-5319744
    (State or other Jurisdiction of
    Incorporation or Organization)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    270 Sylvan Avenue, Suite 2230    
    Englewood Cliffs, NJ   07632
    (Address of Principal Executive Offices)   (zip code)

     

    (201) 899-4470

    (Registrant’s telephone number, including area code)

     

    N/A

    (Former name or former address, if changed since last report)

     

    Securities registered or to be registered as pursuant to Section 12(b) of the Act:

     

    TITLE OF EACH CLASS   TRADING SYMBOL   NAME OF EACH EXCHANGE ON WHICH REGISTERED
    Common stock, $0.00001 par value per share   ATLN   The Nasdaq Global Market

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01. Entry into a Material Definitive Agreement.

     

    The information contained in Item 2.01 of this Current Report on Form 8-K is incorporated herein by reference.

     

    Item 2.01 Completion of Acquisition or Disposition of Assets.

     

    Preferred Stock Purchase Agreement

     

    On March 20, 2026, Atlantic International Corp (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with an institutional investor (the “Purchaser”), whereby it agreed to sell to the Purchaser (the “Offering”), for an aggregate gross purchase price of $5,600,000: (i) an aggregate of 5,600 shares of a newly established series of preferred stock designated as “Series B 5% Convertible Preferred Stock, par value $0.00001 per share” (the “Preferred Stock”), which have a stated value of $1,070 per share, reflecting the original issue discount of 6.5%, and (ii) Preferred Stock Purchase Warrants (the “Warrants”) to purchase an aggregate of an additional 5,600 shares of Preferred Stock (the “Warrant Shares”).

     

    The Offering was completed on March 20, 2026 (the “Closing Date”), subject to customary closing conditions. The net proceeds from the Offering were $5,565,000 after transaction expenses. The Company plans to use the net proceeds for working capital and other general corporate purposes.

     

    As provided in the Purchase Agreement, before the closing of the Offering, the Company filed with the Secretary of State of the State of Delaware a Certificate of Designations, Preferences, Rights and Limitations of Series B 5% Convertible Preferred Stock (the “Certificate of Designations”) to its Amended and Restated Certificate of Incorporation. The Certificate of Designations establishes and sets forth the designations, preferences, powers and rights of the Preferred Stock.

     

    The Preferred Stock ranks senior to the Company’s common stock (the “Common Stock”) with respect to dividends (the Preferred Stock shall pay a dividend of 5.0%, payable in cash or shares of the Preferred Stock) redemption rights, distributions and payments upon the liquidation, dissolution and winding up of the Company, unless the holders of a majority of the outstanding shares of the Preferred Stock consent to the creation of series of preferred stock which will be pari passu or senior to the Preferred Stock.

     

    The Preferred Stock may be converted into such number of shares of Common Stock as equals the stated value of the Preferred Stock divided by the applicable Conversion Price. The Conversion Price is initially equal to $4.38, which was the Closing Price of the Common Stock at the opening of trading on the Closing Date, and will remain fixed for the first 30 calendar days following the Closing Date (the "Initial Conversion Price Period") (the "Initial Conversion Price"). The Initial Conversion Price is subject to adjustment as set forth in the Certificate of Designations.

     

    1

     

     

    The Company may, at any time commencing thirty (30) business days after the Closing Date, at its sole option, purchase back some or all of the Preferred Stock then outstanding, at the price equal to 110% of the value of the outstanding Preferred Stock (the “Optional Redemption Amount”), upon a prior written notice to the Purchaser given at least thirty (30) days before the date of such purchase (the “Optional Redemption Notice”). The Purchaser shall continue to have the right to convert the Preferred Stock at the Conversion Price after receipt of an Optional Redemption Notice and prior to the payment of the Optional Redemption Amount.

     

    Upon the consummation of a Fundamental Transaction by the Company, which includes a merger, sale of all or substantially all the assets of the Company, recapitalization, reorganization, or the sale by the Company of shares resulting in more than 50% ownership by a person or group, the holders of the Preferred Stock shall have the right to convert their shares of Preferred Stock into the shares of common stock of the successor or acquiring corporation or the shares of Common Stock of the Company, if it is the surviving entity, and receive any additional consideration receivable as a result of such Fundamental Transaction by a holder of shares of Common Stock

     

    Upon any issuance by the Company or any of its subsidiaries of Common Stock, Common Stock equivalents for cash consideration, indebtedness or a combination of units thereof (the “Subsequent Financing”), the Purchaser shall have the right to participate in up to 25% of the aggregate amount of such Subsequent Financing on the same terms, conditions and price provided for in the Subsequent Financing, during a period of 24 months after the Closing Date.

     

    The Company shall indemnify the Purchaser and their control persons, affiliates and assignees from and against any and all liabilities which may be incurred by them in connection with the transactions contemplated by the Purchase Agreement, against certain liabilities, including liabilities under the Securities Act and liabilities arising from breaches of representations and warranties contained in the Purchase Agreement.

     

    The Purchase Agreement contains customary representations, warranties and agreements by the Company and customary conditions to closing.

     

    The foregoing descriptions of the terms and conditions of the Purchase Agreement and the Certificate of Designations do not purport to be complete and are qualified by reference to the afore-mentioned documents. The Purchase Agreement and the Certificate of Designations are attached hereto as Exhibits 10.1 and 3.1, respectively, and are incorporated herein by reference. The foregoing summaries of such documents are qualified in their entirety by reference to such exhibits.

     

    Warrants

     

    At the closing, we issued a Preferred Stock Purchase Warrant to purchase 5,600 shares of Preferred Stock, with an exercise price equal to $1,000 per share, subject in each instance to adjustments in the event of the payment of dividends or other distributions, stock splits, subsequent rights offerings, as provided under the terms of the Warrants. The Warrants are exercisable, in full or in part, at any time up to and including the eleven-month anniversary of the Closing Date.

     

    2

     

     

    In the event of a sale of the Company or other Fundamental Transaction prior to the expiration or exercise of the Warrants, the holders of the Warrants shall have a right to receive, for each share of Common Stock that would have been issuable upon conversion of the Warrant Shares that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder, the equivalent number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration receivable as a result of such Fundamental Transaction by a holder of shares of Common Stock.

     

    The foregoing description of the terms and conditions of the Warrants does not purport to be complete and is qualified by reference to the afore-mentioned document. The form of a Warrant is attached as Exhibit 4.1 hereto and is incorporated herein by reference.

     

    Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal year. The information set forth in Item 2.01 of this Current Report on Form 8-K with respect to the Certificate of Designations is incorporated herein by reference

     

    An opinion of Davidoff Hutcher & Citron LLP regarding the validity of the Common stock issuable upon conversion of the Preferred Stock and exercise of the Warrants being issued and sold in the Offering is attached as Exhibit 5.1 hereto.

     

    This Current Report on Form 8-K does not constitute an offer to sell or the solicitation of an offer to buy, and these securities cannot be sold in any state or jurisdiction in which this offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any state or jurisdiction. Any offer will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.

     

    Forward-looking Statements.

     

    The Company notes that the representations, warranties and covenants made by the Company in any agreement that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements. In addition, the assertions embodied in any representations, warranties and covenants contained in such agreements may be subject to qualifications with respect to knowledge and materiality different from those applicable to security holders generally. Moreover, such representations, warranties or covenants were accurate only as of the date when made, except where expressly stated otherwise. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of the Company’s affairs at any time.

     

    This report contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express the Company’s intentions, beliefs, expectations, strategies, predictions or any other statements related to the Company’s future activities, or future events or conditions. These statements are based on current expectations, estimates and projections about the Company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the completion of the Offering, the satisfaction of customary closing conditions related to each, the intended use of net proceeds therefrom, the potential exercise of warrants, as well as those risks discussed in the Company’s Prospectus Supplement, Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and in other documents that the Company files from time to time with the Commission. Any forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this report, except as required by law.

     

    3

     

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.   Description 
    3.1   Certificate of Designations, Preferences, Rights and Limitations of Series B Convertible Preferred Stock.
    4.1   Form of a Preferred Stock Purchase Warrant.
    5.1   Opinion of Davidoff Hutcher and Citron LLP.
    10.1   Securities Purchase Agreement, dated March 20, 2026 by and between Atlantic International Corp and the Purchaser.*
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    * Schedules, exhibits and similar supporting attachments to this exhibit are omitted pursuant to Item 601(a)(5) of Regulation S-K. We agree to furnish a supplemental copy of any omitted schedule or similar attachment to the Securities and Exchange Commission upon request.

     

    4

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: March 26, 2026 ATLANTIC INTERNATIONAL CORP.
         
      By: /s/ Jeffrey Jagid
        Jeffrey Jagid
        Chief Executive Officer

     

    5

     

    Get the next $ATLN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATLN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ATLN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Pfeffer David converted options into 161,290 shares, increasing direct ownership by 10,542% to 162,820 units (SEC Form 4)

    4 - ATLANTIC INTERNATIONAL CORP. (0001605888) (Issuer)

    3/16/26 6:42:00 PM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    New insider Franke Guus Paul Wilhelm claimed ownership of 12,516,070 shares (SEC Form 3)

    3 - ATLANTIC INTERNATIONAL CORP. (0001605888) (Issuer)

    2/10/26 4:05:29 PM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 3 filed by new insider Murphy Kevin James

    3 - ATLANTIC INTERNATIONAL CORP. (0001605888) (Issuer)

    2/5/26 4:30:02 PM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ATLN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Financial Officer Broderick Christopher bought $58 worth of shares (577,171 units at $0.00), increasing direct ownership by 40% to 2,004,237 units (SEC Form 4)

    4/A - ATLANTIC INTERNATIONAL CORP. (0001605888) (Issuer)

    6/25/25 5:11:34 PM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: Chief Executive Officer Jagid Jeffrey M bought $289 worth of shares (2,885,856 units at $0.00), increasing direct ownership by 340% to 3,735,169 units (SEC Form 4)

    4/A - ATLANTIC INTERNATIONAL CORP. (0001605888) (Issuer)

    6/25/25 5:04:40 PM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: General Counsel Tenore Michael bought $58 worth of shares (577,171 units at $0.00), increasing direct ownership by 136% to 1,001,634 units (SEC Form 4)

    4/A - ATLANTIC INTERNATIONAL CORP. (0001605888) (Issuer)

    6/25/25 5:02:59 PM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ATLN
    SEC Filings

    View All

    Atlantic International Corp. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets

    8-K - ATLANTIC INTERNATIONAL CORP. (0001605888) (Filer)

    3/26/26 5:00:07 PM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form DEL AM filed by Atlantic International Corp.

    DEL AM - ATLANTIC INTERNATIONAL CORP. (0001605888) (Filer)

    3/24/26 4:19:00 PM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form S-3 filed by Atlantic International Corp.

    S-3 - ATLANTIC INTERNATIONAL CORP. (0001605888) (Filer)

    3/23/26 11:34:30 AM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ATLN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Atlantic International to Attend 38th Annual ROTH Conference

    ENGLEWOOD CLIFFS, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Atlantic International Corp. (NASDAQ:ATLN), a global provider of outsourced services and workforce solutions, will be participating in the 38th Annual ROTH Conference being held March 22-24, 2026, at the Ritz Carlton in Dana Point, California. Chief Executive Officer Jeffrey Jagid will be representing the company and is available for one-on-one meetings on Monday, March 23rd. Mr. Jagid is expected to discuss Atlantic's recent acquisition of Circle8 and how its integration is strengthening the company's scale and competitive positioning across its outsourced services and workforce solutions platform. He will also address the launch

    3/16/26 8:30:00 AM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Atlantic International Appoints Gateway Group to Lead Investor Relations Program

    ENGLEWOOD CLIFFS, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Atlantic International Corp. (NASDAQ:ATLN), a global provider of outsourced services and workforce solutions, has appointed Gateway Group, a leading strategic corporate and financial communications advisory firm, to lead its investor relations program. Gateway will partner with Atlantic's leadership to strengthen its investor communications strategy and expand engagement within the financial community. The initiative will focus on sharpening the company's messaging and market positioning and expanding outreach to institutional investors and analysts through targeted engagement and conference participation. "Atlantic is entering an

    2/17/26 8:30:00 AM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Atlantic International Strengthens Management Team with Appointment of Kevin J. Murphy as Chief Financial Officer

    ENGLEWOOD CLIFFS, N.J., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Atlantic International Corp. (NASDAQ:ATLN), a global provider of staffing and workforce solutions, today announced the appointment of Kevin J. Murphy, CPA, as Chief Financial Officer, effective February 2, 2026, as the Company continues to scale its platform and integrate recent acquisitions. The appointment follows Atlantic International's acquisition of Circle8 Group, a leading European IT and technology staffing firm, creating a diversified global workforce solutions platform with approximately $1.2 billion (unaudited) in annual revenue. The transaction expanded Atlantic's geographic footprint into key European markets and added

    2/2/26 4:05:00 PM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ATLN
    Leadership Updates

    Live Leadership Updates

    View All

    Atlantic International Appoints Gateway Group to Lead Investor Relations Program

    ENGLEWOOD CLIFFS, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Atlantic International Corp. (NASDAQ:ATLN), a global provider of outsourced services and workforce solutions, has appointed Gateway Group, a leading strategic corporate and financial communications advisory firm, to lead its investor relations program. Gateway will partner with Atlantic's leadership to strengthen its investor communications strategy and expand engagement within the financial community. The initiative will focus on sharpening the company's messaging and market positioning and expanding outreach to institutional investors and analysts through targeted engagement and conference participation. "Atlantic is entering an

    2/17/26 8:30:00 AM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Atlantic International Strengthens Management Team with Appointment of Kevin J. Murphy as Chief Financial Officer

    ENGLEWOOD CLIFFS, N.J., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Atlantic International Corp. (NASDAQ:ATLN), a global provider of staffing and workforce solutions, today announced the appointment of Kevin J. Murphy, CPA, as Chief Financial Officer, effective February 2, 2026, as the Company continues to scale its platform and integrate recent acquisitions. The appointment follows Atlantic International's acquisition of Circle8 Group, a leading European IT and technology staffing firm, creating a diversified global workforce solutions platform with approximately $1.2 billion (unaudited) in annual revenue. The transaction expanded Atlantic's geographic footprint into key European markets and added

    2/2/26 4:05:00 PM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Atlantic International Corp. Appoints Industry Veteran Matt Evelt as Chief Operating Officer to Lead Global Workforce Solutions Strategy

    ENGLEWOOD CLIFFS, N.J., June 02, 2025 (GLOBE NEWSWIRE) -- Atlantic International Corp. (NASDAQ:ATLN), a premier provider of outsourced services, staffing, and workforce solutions, today announced the appointment of Matt Evelt as Chief Operating Officer (COO), effective immediately. Evelt brings more than two decades of leadership experience in workforce strategy, operational transformation, and international expansion. In his new role, he will oversee global operations, drive efficiency, and help scale Atlantic International's delivery of innovative, client-focused staffing and workforce solutions. Evelt most recently served as President – Americas at Airswift, where he successfully led

    6/2/25 1:05:49 PM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ATLN
    Financials

    Live finance-specific insights

    View All

    Atlantic International Corp. Acquires Circle8 Group, Creating a $1.2 Billion Global Workforce Solutions Platform

    ENGLEWOOD CLIFFS, N.J., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Atlantic International Corp. (NASDAQ:ATLN), a leading provider of strategic staffing and workforce solutions, today announced the acquisition of Circle8 Group. The transaction creates a diversified global workforce solutions platform with $1.2 billion (unaudited) in annual revenue, uniting Atlantic's North American light industrial staffing operations with Circle8's leading European IT and technology talent business. Acquisition Summary Creates a diversified global workforce solutions platform with approximately $1.2 billion (unaudited) in annual revenueExpands Atlantic's geographic footprint into key European marketsAdds high-gro

    1/23/26 8:00:00 AM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Atlantic International Corp. Reports Strong 2024 Results with Over $442 Million in Revenue; Over 10% Revenue Growth

    Company Completes First Quarter Publicly-Traded on Nasdaq Global Market under "ATLN" Announces Strategic Developments and Outlook; Targets $1 to $1.5 Billion Revenue from Both Organic Growth and M&A Initiatives in the Next 12 to 18 Months ENGLEWOOD CLIFFS, N.J., March 28, 2025 (GLOBE NEWSWIRE) -- Atlantic International Corp. ("Atlantic" or the "Company") (NASDAQ:ATLN), a leading provider of strategic staffing, outsourced services and workforce solutions, today announced its financial results for the fourth quarter and full year ended December 31, 2024. Key Financial Highlights: Q4 2024 Revenue: Revenue for the fourth quarter was $129.5 million, representing an 11.5% increase from $116.

    3/28/25 7:30:00 AM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials